NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report) saw a significant drop in short interest in July. As of July 15th, there was short interest totalling 52,700 shares, a drop of 43.1% from the June 30th total of 92,600 shares. Based on an average daily trading volume, of 59,500 shares, the short-interest ratio is presently 0.9 days. Approximately 16.2% of the shares of the stock are short sold.
Wall Street Analyst Weigh In
Separately, Maxim Group initiated coverage on shares of NeuroBo Pharmaceuticals in a report on Wednesday, May 8th. They issued a “buy” rating and a $10.00 target price for the company.
Read Our Latest Analysis on NRBO
Insider Buying and Selling at NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals Stock Up 1.3 %
Shares of NRBO stock traded up $0.06 during trading hours on Friday, hitting $4.15. The company’s stock had a trading volume of 14,553 shares, compared to its average volume of 615,435. The business has a fifty day moving average of $4.29 and a 200-day moving average of $4.23. NeuroBo Pharmaceuticals has a twelve month low of $2.90 and a twelve month high of $6.75.
NeuroBo Pharmaceuticals (NASDAQ:NRBO – Get Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.37). Equities analysts expect that NeuroBo Pharmaceuticals will post -4.89 earnings per share for the current fiscal year.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.
Recommended Stories
- Five stocks we like better than NeuroBo Pharmaceuticals
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How is Compound Interest Calculated?
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.